Skip To Main Content
InFlames Flagship on Muck Rack

InFlames Flagship

As seen in: Oxford Academic, Biomed Central (BMC), The American Journal of Human Genetics, Cell Press, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with InFlames

Contact InFlames, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Household Transmission and Clinical Features of SARS-CoV-2-Positive and -Negative Respiratory Tract Infections

|
By InFlames Flagship
| Oxford Academic Verified
Comparative data on the transmission of respiratory infections positive and negative for SARS-CoV-2 in households with children are limited. In June–August 2020, we recruited 700 participants (175 households, 376 children, 324 adults) to be prospectively followed for all respiratory tract infections. Follow-up lasted from recruitment till April 2022. Daily symptoms were monitored by weekly electronic questionnaires.
Open in Who Shared Issue with article?

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

|
By Jenna Rannikko, InFlames Flagship, Loic Verlingue, Institut Gustave Roussy
| Cell Reports Medicine Verified
Highlights • Targeting Clever-1 with bexmarilimab is well tolerated • Disease control in late-stage cancer can be achieved with bexmarilimab monotherapy • Low baseline immune activation associates with bexmarilimab benefit • Bexmarilimab converts intratumoral macrophages to support adaptive immune responses Summary Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity.
Open in Who Shared Issue with article?

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

|
By Jenna Rannikko, InFlames Flagship, Institut Gustave Roussy, Maria de Miguel
| Cell Reports Medicine Verified
Highlights • Targeting Clever-1 with bexmarilimab is well tolerated • Disease control in late-stage cancer can be achieved with bexmarilimab monotherapy • Low baseline immune activation associates with bexmarilimab benefit • Bexmarilimab converts intratumoral macrophages to support adaptive immune responses Summary Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity.
Open in Who Shared Issue with article?
See all 6 articles